Please login to the form below

Not currently logged in
Email:
Password:

Targovax strengthens board of directors

Catherine Wheeler joins from Acetylon Pharmaceutical

Clinical stage company Targovax has added to its board of directors with the appointment of Catherine Wheeler.

Most recently, Wheeler served Acetylon Pharmaceutical as chief medical officer and prior to that she held progressively senior clinical and business development roles at Roche, AstraZeneca and Parexel.

Patrick Vink, chairman of the board at Targovax, said: “We are delighted to welcome Catherine, she brings extensive international oncology expertise and insights that will further strengthen the board.

“She has had a long and distinguished career and has significant experience of bringing innovative oncology treatments to market that will be invaluable as we continue to progress the clinical development of our novel and complementary portfolio of cancer immunotherapies.”

18th April 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....